UPDATE: Goldman Sachs Maintains Neutral Rating on ViroPharma, Lowers PT

Goldman Sachs reduced their Viropharma

estimates following a release of generic versions of their drug Vanco. Goldman Sachs went on to say, “…we are reducing our VPHM estimates for 2012-2015. This drives a decrease in our 12-month price target, equally based on our DCF/SOTP analyses, to $22 from $26.” VPHM closed yesterday at $22.44.